nach oben

Erschienen in:

01.02.2012 | Clinical Study - Patient Study

A phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: a Pediatric Brain Tumor Consortium study

verfasst von: Katherine E. Warren, Sri Gururangan, J. Russell Geyer, Roger E. McLendon, Tina Young Poussaint, Dana Wallace, Frank M. Balis, Stacey L. Berg, Roger J. Packer, Stewart Goldman, Jane E. Minturn, Ian F. Pollack, James M. Boyett, Larry E. Kun

Erschienen in: Journal of Neuro-Oncology | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

To estimate the sustained (≥8 weeks) objective response rate in pediatric patients with recurrent or progressive high-grade gliomas (HGG, Stratum A) or brainstem gliomas (BSG, Stratum B) treated with the combination of O6-benzylguanine (O6BG) and temozolomide^® (TMZ). Patients received O6BG 120 mg/m²/d IV followed by TMZ 75 mg/m²/d orally daily for 5 consecutive days of each 28-day course. The target objective response rate to consider the combination active was 17%. A two-stage design was employed. Forty-three patients were enrolled; 41 were evaluable for response, including 25 patients with HGG and 16 patients with BSG. The combination of O6BG and TMZ was tolerable, and the primary toxicities were myelosuppression and gastrointestinal symptoms. One sustained (≥8 weeks) partial response was observed in the HGG cohort; no sustained objective responses were observed in the BSG cohort. Long-term (≥6 courses) stable disease (SD) was observed in 4 patients in Stratum A and 1 patient in Stratum B. Of the 5 patients with objective response or long-term SD, 3 underwent central review with 2 reclassified as low-grade gliomas. The combination of O6BG and TMZ did not achieve the target response rate for activity in pediatric patients with recurrent or progressive HGG and BSG.

Friedman H, Dolan M, Pegg A et al (1995) Activity of temozolomide in the treatment of central nervous system xenografts. Cancer Res 55:2853–2857PubMed

Stupp R, Hegi M, Gilbert M, Chakravarti A (2007) Chemoradiotherapy in malignant glioma: Standard of care and future directions. J Clin Oncol 25:4127–4136PubMedCrossRef

Yung A, Prados M, Yaya-Tur R et al (1999) Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. J Clin Oncol 17:2762–2771PubMed

Brada M, Hoang-Xuan K, Rampling R et al (2006) Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol 12:259–266CrossRef

Sankar A, Thomas D, Darling J (1999) Sensitivity of short-term cultures derived from human malignant glioma to the anti-cancer drug temozolomide. Anticancer Drugs 10:179–185PubMedCrossRef

Stupp R, Dietrich P, Ostermann K et al (2002) Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 20:1375–1382PubMedCrossRef

Chibbaro S, Benvenuti L, Caprio A et al (2004) Temozolomide as first-line agent in treating high-grade gliomas: phase II study. J Neurooncol 67:77–81PubMedCrossRef

Lashford L, Thiesse P, Jouvet A et al (2002) Temozolomide in malignant gliomas of childhood: a United Kingdom Children’s Cancer Study Group and French Society for Pediatric Oncology Intergroup Study. J Clin Oncol 20:4684–4691PubMedCrossRef

Broniscer A, Iacono L, Chintagumpala M et al (2005) Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children: results of a multiinstitutional study (SJHG-98). Cancer 103:133–139PubMedCrossRef

10.

Nicholson H, Kretschmar C, Krailo M et al (2007) Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children’s Oncology Group. Cancer 110:1542–1550PubMedCrossRef

11.

Cohen K, Pollack I, Zhou T et al (2011) Temozolomide in the treatment of high-grade gliomas in children: a report from the Children’s Oncology Group. Neuro Oncology 13:317–323PubMedCrossRef

12.

Cohen K, Heideman R, Zhou T et al (2011) Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children’s Oncology Group. Neuro Oncology 13:410–416PubMedCrossRef

13.

Bobola M, Silber J, Ellenbogen R et al (2005) O⁶-methylguanine-DNA-methyltransferase, O⁶-benzylguanine, and resistance to alkylators in pediatric primary brain tumor cell lines. Clin Cancer Res 11:2747–2755PubMedCrossRef

14.

Donson A, Addo-Yobo S, Handler M et al (2007) MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastomas. Pediatr Blood Cancer 48:403–407PubMedCrossRef

15.

Denny B, Wheelhouse R, Stevens M et al (1994) NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. Biochemistry 33:9045–9051PubMedCrossRef

16.

Stevens M, Hickman J, Langdon S et al (1987) Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5, 1-d]-1, 2, 3, 5-terazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res 47:5846–5852PubMed

17.

Hegi M, Liu L, Herman J et al (2008) Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 26:4189–4199PubMedCrossRef

18.

Roos W, Batista L, Naumann S et al (2007) Apoptosis in malignant glioma cells triggered by temozolomide-induced DNA lesion O6-methylguanine. Oncogene 26:186–197PubMedCrossRef

19.

Friedman H, McLendon R, Kerby T et al (1998) DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol 16:3851–3857PubMed

20.

Kokkinakis D, Bocangel D, Schold S et al (2001) Thresholds of O6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1, 3-bis(2-chloroethyl)-1-nitrosourea or temozolomide. Clin Cancer Res 7:421–428PubMed

21.

Gerson S (2002) Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol 20:2388–2399PubMedCrossRef

22.

Ishii D, Natsume A, Wakabayashi T et al (2007) Efficacy of temozolomide is correlated with 1p loss and methylation of the deoxyribonucleic acid repair gene MGMT in malignant gliomas. Neurol Med Chir (Tokyo) 47:341–349CrossRef

23.

Friedman H, Keir S, Pegg A et al (2002) O6-benzylguanine-mediated enhancement of chemotherapy. Mol Cancer Ther 1:943–948PubMed

24.

Wedge S, Newlands E (1996) O6-benzylguanine enhances the sensitivity of a glioma xenograft with low O6-alkylguanine-DNA alkyltransferase activity to temozolomide and BCNU. Br J Cancer 73:1049–1052PubMedCrossRef

25.

Warren K, Aikin A, Libucha M et al (2005) Phase I study of O6-benzylguanine and temozolomide administered daily for 5 days to pediatric patients with solid tumors. J Clin Oncol 23:7646–7653PubMedCrossRef

26.

Broniscer A, Gururangan S, MacDonald T et al (2007) Phase I trial of single-dose temozolomide and continuous administration of O6-benzylguanine in children with brain tumors: a pediatric brain tumor consortium report. Clin Cancer Res 13:6712–6718PubMedCrossRef

27.

Maxwell J, Johnson S, Quinn J et al (2006) Quantitative analysis of O6-alkylguanine-DNA-alkyltransferase in malignant glioma. Mol Cancer Ther 5:2531–2539PubMedCrossRef

28.

Rich J, Sathornsumetee S, Keir S et al (2005) ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors. Clin Cancer Res 11:8145–8157PubMedCrossRef

29.

Brandes A, Ermani M, Basso U et al (2002) Temozolomide in patients with glioblastoma at second relapse after first line nitrosourea-procarbazine failure: a phase II study. Oncology 63:38–41PubMedCrossRef

30.

Quinn J, Jiang S, Reardon D et al (2009) Phase II trial of temozolomide plus O6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. J Clin Oncol 27:1262–1267PubMedCrossRef

31.

Quinn J, Pluda J, Dolan M et al (2002) Phase II trial of carmustine plus O6-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. J Clin Oncol 20:2277–2283PubMedCrossRef

32.

Brandes A, Tosoni A, Cavallo G et al (2006) Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study. J Clin Oncol 24:4746–4753PubMedCrossRef

33.

Donson A, Addo-Yobo S, Handler M et al (2007) MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma. Pediatr Blood Cancer 48:403–407PubMedCrossRef

34.

Newlands E (1992) Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer 65:287–291PubMedCrossRef

35.

Patel M, McCully C, Godwin K et al (2003) Plasma and cerebrospinal fluid pharmacokinetics of intravenous temozolomide in non-human primates. J Neurooncol 61:203–207PubMedCrossRef

36.

Panetta J, Kirstein M, Gajjar A et al (2003) Population pharmacokinetics of temozolomide and metabolites in infants and children with primary central nervous system tumors. Cancer Chemother Pharmacol 52:435–441PubMedCrossRef

37.

Berg S, Gerson S, Godwin K et al (1995) Plasma and cerebrospinal fluid pharmacokinetics of O6-benzylguanine and time course of peripheral blood mononuclear cell O6-methylguanine-DNA methyltransferase inhibition in the nonhuman primate. Cancer Res 55:4604–4610

38.

Friedman H, Kokkinakis D, Pluda J et al (1998) Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma. J Clin Oncol 16:3570–3575PubMed

39.

Karran P, Bignami M (1994) DNA damage tolerance, mismatch repair and genome instability. Bioessays 16:833–839PubMedCrossRef

Titel: A phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: a Pediatric Brain Tumor Consortium study
verfasst von: Katherine E. Warren
Sri Gururangan
J. Russell Geyer
Roger E. McLendon
Tina Young Poussaint
Dana Wallace
Frank M. Balis
Stacey L. Berg
Roger J. Packer
Stewart Goldman
Jane E. Minturn
Ian F. Pollack
James M. Boyett
Larry E. Kun
Publikationsdatum: 01.02.2012
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology / Ausgabe 3/2012
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-011-0709-z

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Viertel reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Bluttest erkennt Parkinson schon zehn Jahre vor der Diagnose

10.05.2024 Parkinson-Krankheit Nachrichten

Ein Bluttest kann abnorm aggregiertes Alpha-Synuclein bei einigen Menschen schon zehn Jahre vor Beginn der motorischen Parkinsonsymptome nachweisen. Mit einem solchen Test lassen sich möglicherweise Prodromalstadien erfassen und die Betroffenen früher behandeln.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Wartezeit nicht kürzer, aber Arbeit flexibler

Psychotherapie Medizin aktuell

Fünf Jahren nach der Neugestaltung der Psychotherapie-Richtlinie wurden jetzt die Effekte der vorgenommenen Änderungen ausgewertet. Das Hauptziel der Novellierung war eine kürzere Wartezeit auf Therapieplätze. Dieses Ziel wurde nicht erreicht, es gab jedoch positive Auswirkungen auf andere Bereiche.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2012

Pediatric infratentorial ependymoma: prognostic significance of anaplastic histology

Oxcarbazepine monotherapy in patients with brain tumor-related epilepsy: open-label pilot study for assessing the efficacy, tolerability and impact on quality of life

Regulation of histone acetylation by NDRG2 in glioma cells

A phase II trial of thalidomide and procarbazine in adult patients with recurrent or progressive malignant gliomas

R-flurbiprofen, a novel nonsteroidal anti-inflammatory drug, decreases cell proliferation and induces apoptosis in pituitary adenoma cells in vitro